A Framework for Fitness-for-Purpose and Reuse in Computational Phenotyping
November 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Zometa, Reclast
Synonyms :
Zoledronic acid, Zoledronate
Class :
Bisphosphonates
Brand Name :
Zometa, Reclast
Synonyms :
Zoledronic acid, Zoledronate
Class :
Bisphosphonates
Dosage Forms & Strengths
Injectable solution
4mg/5mL (5mL)
5mg/100mL
Safety and efficacy not established
Refer adult dosing
It may decrease the effects of human parathyroid hormone
may diminish the serum concentration of polyvalent cation-containing products
may diminish the serum concentration of Polyvalent Cation Containing Products
aluminum hydroxide/magnesium carbonate
may decrease the serum concentration of Polyvalent Cation Containing Products
may decrease the serum concentration of Polyvalent Cation Containing Products
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
may decrease the serum concentration and decrease in the efficacy
may diminish the serum concentration of polyvalent cation-containing products
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
It may enhance the risk of adverse effects when combined with vitamins
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
may have an increasingly adverse effect when combined with bisphosphonate derivatives
combining isoxicam with zoledronic acid may raise the risk of gastrointestinal bleeding
the risk or severity of gastrointestinal bleeding can be raised when sulindac is used in combination
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
bisphosphonate derivatives increase the toxicity of deferasirox
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may increase the hypo calcaemic effect
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of angiogenesis inhibitors
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
neomycin/polymyxin B/bacitracin topical
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
It may increase the nephrotoxic effect when combined with Bisphosphonate Derivatives
It may increase the toxic effect when combined with Bisphosphonate Derivatives
It may enhance the risk of adverse effects when combined with Phosphodiesterase inhibitors
the severity of gastrointestinal bleeding can be enhanced when mofebutazone is administered with zoledronic acid
ferrous bisglycinate may cause a decrease in the absorption of zoledronic acid, leading to reduced serum concentration and potentially compromising efficacy
ferrous succinate has the potential to impair zoledronic acid absorption, which could compromise efficacy by lowering serum levels
may have an increasingly adverse effect when combined with bisphosphonate derivatives
the risk of anti-angiogenesis and jaw osteonecrosis may be increased
the risk of anti-angiogenesis and jaw osteoporosis may be increased
the risk of gastrointestinal bleeding may be increased
the risk of gastrointestinal bleeding may be increased
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
may have an increasingly adverse effect when combined with bisphosphonate derivatives
zoledronic acid is a medication primarily used to treat conditions involving bone, such as osteoporosis and bone metastases in cancer.
Action:
Bone Resorption Inhibitor: zoledronic acid is a potent inhibitor of osteoclasts, cells responsible for breaking down bone tissue. It reduces bone resorption, which helps maintain bone density and strength.
Spectrum:
Osteoporosis: Zoledronic acid is used to treat osteoporosis in postmenopausal women and men at risk of fractures. It helps increase bone mineral density and reduce the risk of fractures.
Cancer-Related Bone Disease: zoledronic acid is also used in cancer patients with bone metastases. It can reduce pain, prevent skeletal complications, and improve the quality of life in these patients.
Hypercalcemia: In cases of hypercalcemia (high blood calcium levels) due to cancer, zoledronic acid can be administered to lower calcium levels in the blood.
Paget’s Disease: zoledronic acid is sometimes prescribed for Paget’s disease, a condition characterized by abnormal bone remodeling. It helps control bone turnover and reduce pain.
Prevention of Bone Loss: It may be prescribed to prevent bone loss in individuals undergoing long-term corticosteroid therapy.
Dental Procedures: zoledronic acid is associated with a risk of osteonecrosis of the jaw (ONJ). Dentists often consider the patient’s history of zoledronic acid use before certain dental procedures.
Frequency Defined
>10%
Anxiety
Hypophosphatemia
Bone pain
Nausea
Anemia
Vomiting
Constipation
Dizziness
Insomnia
Urinary tract infection
Rash
Frequency Not Defined
Uveitis
Scleritis
Episcleritis
Conjunctivitis
Iritis
orbital inflammation
Black Box Warning:
The warning primarily highlights the risk of renal (kidney) impairment, including acute kidney injury. Patients taking zoledronic acid should be carefully monitored for kidney function before and after each dose.
Pregnancy warnings:
Pregnancy Category: N/A
Breastfeeding warnings:
crosses into breast milk- unknown
Pregnancy Categories:
Patient Information Leaflet
Generic Name: zoledronic acid
Why do we use zoledronic acid?
zoledronic acid is a medication primarily used to treat and prevent bone-related conditions. It’s commonly employed for the following reasons:
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
